Biophytis Files Routine 6-K Report
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, 6-K
TL;DR
Biophytis filed a 6-K, just routine stuff, no big news.
AI Summary
Biophytis S.A. filed a Form 6-K on September 15, 2025. The filing is a report of a foreign private issuer and does not contain specific financial details or significant events beyond its routine reporting nature. The company's principal executive office is located at Sorbonne University in Paris, France.
Why It Matters
This filing indicates Biophytis S.A. is fulfilling its reporting obligations as a foreign private issuer, but it does not disclose new material information.
Risk Assessment
Risk Level: low — This filing is a standard report and does not contain any new material information that would alter the company's risk profile.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Stanislas Veillet (person) — Contact Person
- Sorbonne University (company) — Company Address
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
When was this report filed?
The report was filed on September 15, 2025.
Where is Biophytis S.A. located?
Biophytis S.A.'s principal executive office is located at Sorbonne University, BC 9, Bâtiment A 4ème étage, 4 place Jussieu, 75005 Paris, France.
Does this filing indicate the company is submitting its annual report?
The filing indicates the company may file annual reports under Form 20-F, but this 6-K itself is not an annual report.
Is Biophytis S.A. a US-based company?
No, Biophytis S.A. is identified as a foreign private issuer, and its business address is a non-US location.
Filing Stats: 250 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-09-15 11:54:32
Filing Documents
- tm2526089d1_6k.htm (6-K) — 11KB
- tm2526089d1_ex99-1.htm (EX-99.1) — 17KB
- tm2526089d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-25-089885.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOPHYTIS S.A. Date: September 15, 2025 By: /s/ Stanislas Veillet Name: Stanislas Veillet Title: Chairman and Chief Executive Officer